A trial to study bioequivalence of fixed dose combination (Fdc) tablets of linagliptin/metformin extended release compared with the free combinations in healthy volunteers

Trial Profile

A trial to study bioequivalence of fixed dose combination (Fdc) tablets of linagliptin/metformin extended release compared with the free combinations in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Linagliptin/metformin (Primary) ; Linagliptin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 Apr 2016 New trial record
    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top